JP7774573B2 - トリアゾロン化合物 - Google Patents

トリアゾロン化合物

Info

Publication number
JP7774573B2
JP7774573B2 JP2022558345A JP2022558345A JP7774573B2 JP 7774573 B2 JP7774573 B2 JP 7774573B2 JP 2022558345 A JP2022558345 A JP 2022558345A JP 2022558345 A JP2022558345 A JP 2022558345A JP 7774573 B2 JP7774573 B2 JP 7774573B2
Authority
JP
Japan
Prior art keywords
pyridyl
amino
triazolo
pyrimidin
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022558345A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023519361A (ja
JP2023519361A5 (https=
Inventor
アルバート ブラウン，ジレス
スチュアート コングリーブ，マイルズ
メアリー リチャードソン，クリスティン
ポール，レベッカ
フィリップ アンドリューズ，スティーブン
スティーブン メイソン，ジョナサン
デフロリアン，フランチェスカ
アラン スウェイン，ナイジェル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nxera Pharma UK Ltd
Original Assignee
Nxera Pharma UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nxera Pharma UK Ltd filed Critical Nxera Pharma UK Ltd
Publication of JP2023519361A publication Critical patent/JP2023519361A/ja
Publication of JP2023519361A5 publication Critical patent/JP2023519361A5/ja
Application granted granted Critical
Publication of JP7774573B2 publication Critical patent/JP7774573B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2022558345A 2020-03-26 2021-03-25 トリアゾロン化合物 Active JP7774573B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062994970P 2020-03-26 2020-03-26
US62/994,970 2020-03-26
PCT/EP2021/057807 WO2021191379A1 (en) 2020-03-26 2021-03-25 5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer

Publications (3)

Publication Number Publication Date
JP2023519361A JP2023519361A (ja) 2023-05-10
JP2023519361A5 JP2023519361A5 (https=) 2024-04-01
JP7774573B2 true JP7774573B2 (ja) 2025-11-21

Family

ID=75339741

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022558345A Active JP7774573B2 (ja) 2020-03-26 2021-03-25 トリアゾロン化合物

Country Status (8)

Country Link
US (1) US12528815B2 (https=)
EP (1) EP4126873A1 (https=)
JP (1) JP7774573B2 (https=)
KR (1) KR20230051118A (https=)
CN (1) CN115867280B (https=)
AU (1) AU2021243725A1 (https=)
CA (1) CA3177056A1 (https=)
WO (1) WO2021191379A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025512384A (ja) 2022-04-13 2025-04-17 ギリアード サイエンシーズ， インコーポレイテッド Ｔｒｏｐ－２発現がんを治療するための併用療法
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006138734A1 (en) 2005-06-17 2006-12-28 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
JP2011513417A (ja) 2008-03-04 2011-04-28 シェーリング コーポレイション アデノシンＡ２ａ受容体アンタゴニストとして使用するための１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オンおよびピラゾロ［４，３−ｅ］−１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オン化合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE457988T1 (de) 2006-06-26 2010-03-15 Schering Corp A2a-adenosin-rezeptor-antagonisten
AU2011306358B2 (en) 2010-09-24 2014-08-14 Impetis Biosciences Ltd. Fused tricyclic compounds as adenosine receptor antagonist
EP3277689B1 (en) 2015-04-03 2019-09-04 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
AU2018233367B2 (en) 2017-03-16 2021-08-12 Jiangsu Hengrui Medicine Co., Ltd. Heteroaryl[4,3-c]pyrimidine-5-amine derivative, preparation method therefor, and medical uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006138734A1 (en) 2005-06-17 2006-12-28 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
JP2011513417A (ja) 2008-03-04 2011-04-28 シェーリング コーポレイション アデノシンＡ２ａ受容体アンタゴニストとして使用するための１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オンおよびピラゾロ［４，３−ｅ］−１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オン化合物

Also Published As

Publication number Publication date
CN115867280B (zh) 2025-05-27
CA3177056A1 (en) 2021-09-30
US12528815B2 (en) 2026-01-20
JP2023519361A (ja) 2023-05-10
EP4126873A1 (en) 2023-02-08
KR20230051118A (ko) 2023-04-17
CN115867280A (zh) 2023-03-28
AU2021243725A1 (en) 2022-10-27
WO2021191379A1 (en) 2021-09-30
US20230146483A1 (en) 2023-05-11

Similar Documents

Publication Publication Date Title
EP2651899B1 (en) Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof
CA2948587C (en) Pyrazolopyridines and pyrazolopyrimidines
CN116406271B (zh) 双环类化合物
JP6430512B2 (ja) リジン特異的デメチラーゼ−１の阻害剤
CA2927252C (en) Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
TW201946629A (zh) Mat2a之雜双環抑制劑及治療癌症之使用方法
AU2015320142B2 (en) Novel imidazopyridazine compounds and their use
CA3142340A1 (en) Heterobicyclic inhibitors of mat2a and methods of use for treating cancer
EP3784671B1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
TW201127385A (en) N-containing heteroaryl derivatives as JAK3 kinase inhibitors
WO2015025026A1 (en) Alkynyl alcohols and methods of use
CN113121575A (zh) 一种(取代的苯基)(取代的嘧啶)胺基衍生物及其制备方法和药物用途
TW202023559A (zh) 吡化合物及其用途
CA2698753A1 (en) Pyrazolo-pyridines as tyrosine kinase inhibitors
JP7774573B2 (ja) トリアゾロン化合物
TW202144333A (zh) 醯胺類化合物及其用途
JP7675094B2 (ja) トリアゾロン化合物
CN117466897A (zh) 高选择性fgfr2抑制剂
JP7709454B2 (ja) トリアゾロン化合物
TW202110801A (zh) 新型醯胺類化合物及其用途
TWI690528B (zh) 稠環雙環吡啶基衍生物
WO2025207620A1 (en) Akt1 modulators
CN121773105A (zh) Cbl-b抑制剂及其应用
TW202220988A (zh) 雜芳環類化合物及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240319

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240319

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250128

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250414

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250924

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251021

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251111

R150 Certificate of patent or registration of utility model

Ref document number: 7774573

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150